Research programme: monoclonal antibodies - Abeome
Latest Information Update: 14 Apr 2011
At a glance
- Originator Abeome Corporation
- Developer Abeome Corporation; Cato Research
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 14 Apr 2011 Preclinical development is ongoing in USA
- 15 Jul 2008 Preclinical trials in Ovarian cancer in USA (IV)